A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

November 11, 2020

Primary Completion Date

November 17, 2023

Study Completion Date

November 17, 2023

Conditions

Non-small Cell Lung Carcinoma (NSCLC)

Interventions

DRUG

Capmatinib

400 mg administered orally twice daily